Hemocompatibility is the goal for any biomaterial contained in extracorporeal life supporting medical devices. The hallmarks for hemocompatibility include nonthrombogenicity, platelet preservation, and maintained platelet function. Both in vitro and in vivo assays testing for compatibility of the blood/biomaterial interface have been used over the last several decades to ascertain if the biomaterial used in medical tubing and devices will require systemic anticoagulation for viability. Over the last 50 years systemic anticoagulation with heparin has been the gold standard in maintaining effective extracorporeal life supporting. However, the biomaterial that maintains effective ECLS without the use of any systemic anticoagulant has remained elusive. In this review, the in vivo 4-h rabbit thrombogenicity model genesis will be described with emphasis on biomaterials that may require no systemic anticoagulation for extracorporeal life supporting longevity. These novel biomaterials may improve extracorporeal circulation hemocompatibility by preserving near resting physiology of the major blood components, the platelets and monocytes. The rabbit extracorporeal circulation model provides a complete assessment of biomaterial interactions with the intrinsic coagulation players, the circulating platelet and monocytes. This total picture of blood/biomaterial interaction suggests that this rabbit thrombogenicity model could provide a standardization for biomaterial hemocompatibility testing.
ReynoldsMMAnnichGM. The artificial endothelium. Organogenesis2011; 7: 42–49.
2.
RajagopalSKAlmondCSLaussenPC. Extracorporeal membrane oxygenation for the support of infants, children, and young adults with acute myocarditis: a review of the extracorporeal life support organization registry. Crit Care Med2010; 38: 382–387.
3.
GaffneyAMWildhirtSMGriffinMJ. Extracorporeal life support. BMJ2010; 341: c5317–c5317.
4.
Van Meurs K, Zwischenberger JB and Extracorporeal Life Support Organization. ECMO : extracorporeal cardiopulmonary support in critical care. Third ed. [Ann Arbor, Mich.]: Extracorporeal Life Support Organization, 2005, pp.xxiii, 625.
5.
GbadegesinRZhaoSCharpieJ. Significance of hemolysis on extracorporeal life support after cardiac surgery in children. Pediatr Nephrol2009; 24: 589–595.
6.
KjærgaardBKristensenSRRisomM. A porcine model of massive, totally occlusive, pulmonary embolism. Thrombosis Research2009; 124: 226–229.
7.
RanucciMBalduiniADittaA. A systematic review of biocompatible cardiopulmonary bypass circuits and clinical outcome. Ann Thorac Surg2009; 87: 1311–1319.
8.
JanvierGBaqueyCRothC. Extracorporeal circulation, hemocompatibility, and biomaterials. Ann Thorac Surg1996; 62: 1926–1934.
9.
KallmesDFMcGrawJKEvansAJ. Effects of systemic heparinization on the thrombogenicity of hydrophilic and nonhydrophilic catheters in a swine model. Neuroradiology1998; 40: 530–535.
10.
LoBFijnheerRCastigliegoD. Activation of hemostasis after coronary artery bypass grafting with or without cardiopulmonary bypass. Anesth Analg2004; 99: 634–640.
11.
KocakulakMOzgurtasTAyhanH. Effect of poly (2-methoxyethyl acrylate)-coated oxygenators on haemolysis. J Biomater Sci Polym Ed2006; 17: 449–460.
12.
ZimmermannAKAebertHReizA. Hemocompatibility of PMEA coated oxygenators used for extracorporeal circulation procedures. ASAIO J2004; 50: 193–199.
13.
SaitoNMotoyamaSSawamotoJ. Effects of new polymer-coated extracorporeal circuits on biocompatibility during cardiopulmonary bypass. Artif Organs2000; 24: 547–554.
14.
NewlandRFBakerRASandersonAJ. Oxygenator safety evaluation: a focus on connection grip strength and arterial temperature measurement accuracy. J Extra Corpor Technol2012; 44: 53–59.
15.
OttensJBakerRASandersonAJ. Disconnection of Cobe SMARxT tubing from the venous outlet of the Terumo Capiox SX25RX oxygenator during cardiopulmonary bypass. J Extra Corpor Technol2010; 42: 153–157.
16.
UrbanKRedfordDLarsonDF. Insulin binding to the cardiopulmonary bypass biomaterials. Perfusion2007; 22: 207–210.
17.
SudkampMMehlhornUReza RajiM. Cardiopulmonary bypass copolymer surface modification reduces neither blood loss nor transfusions in coronary artery surgery. Thorac Cardiovasc Surg2002; 50: 5–10.
18.
Ambert-BalayKPothierP. Evaluation of 4 immunochromatographic tests for rapid detection of norovirus in faecal samples. Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology2013; 56: 194–198.
19.
Ogouyemi-HountoAKinde-GazardDKekeC. Assessment of a rapid diagnostic test and portable fluorescent microscopy for malaria diagnosis in Cotonou (Benin). Bulletin de la Societe de pathologie exotique2013; 106: 27–31.
20.
ChoCHWooMKKimJY. Evaluation of five rapid diagnostic kits for influenza A/B virus. J Virol Methods2013; 187: 51–56.
21.
DorniaCPhilippABauerS. Visualization of thrombotic deposits in extracorporeal membrane oxygenation devices using multidetector computed tomography: a feasibility study. ASAIO J2013; 59: 439–441.
22.
NsaghaDSNjundaALKamgaHL. HIV-1/HIV-2 co-infection among voluntary counselling and testing subjects at a regional hospital in Cameroon. Afr Health Sci2012; 12: 276–281.
23.
AndriesACDuongVNganC. Field evaluation and impact on clinical management of a rapid diagnostic kit that detects dengue NS1, IgM and IgG. PLoS Negl Trop Dis2012; 6: e1993–e1993.
24.
KosasihHWidjajaSSuryaE. Evaluation of two IgM rapid immunochromatographic tests during circulation of Asian lineage Chikungunya virus. Southeast Asian J Trop Med Public Health2012; 43: 55–61.
25.
KimHSHyunJKimJS. Evaluation of the SD Bioline Norovirus rapid immunochromatography test using fecal specimens from Korean gastroenteritis patients. J Virol Methods2012; 186: 94–98.
26.
DalabihAPietschJJabsK. Extracorporeal membrane oxygenation as a platform for recovery: a case report of a child with pulmonary hemorrhage, refractory hypoxemic respiratory failure, and new onset goodpasture syndrome. J Extra Corpor Technol2012; 44: 75–77.
27.
VadwaiVSadaniMSableR. Immunochromatographic assays for detection of Mycobacterium tuberculosis: what is the perfect time to test?Diagn Microbiol Infect Dis2012; 74: 282–287.
28.
ReserDSeifertBKleinM. Retrospective analysis of outcome data with regards to the use of Phisio(R)-, Bioline(R)- or Softline(R)-coated cardiopulmonary bypass circuits in cardiac surgery. Perfusion2012; 27: 530–534.
29.
KanadeSNatarajGSuryawanshiR. Utility of MPT 64 antigen detection assay for rapid characterization of mycobacteria in a resource constrained setting. The Indian journal of tuberculosis2012; 59: 92–96.
30.
SilpasakornSWaywaDHoontrakulS. Performance of SD Bioline Tsutsugamushi assays for the diagnosis of scrub typhus in Thailand. J Med Assoc Thai2012; 95(Suppl 2): S18–S22.
31.
PicotJHartwellDHarrisP. The effectiveness of interventions to treat severe acute malnutrition in young children: a systematic review. Health Technol Assess2012; 16: 1–316.
32.
ChettyVMoodleyDChuturgoonA. Evaluation of a 4th generation rapid HIV test for earlier and reliable detection of HIV infection in pregnancy. Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology2012; 54: 180–184.
33.
FiersTCasettaBBernaertB. Development of a highly sensitive method for the quantification of estrone and estradiol in serum by liquid chromatography tandem mass spectrometry without derivatization. J Chromatogr B Analyt Technol Biomed Life Sci2012; 893–894: 57–62.
34.
ChinkhumbaJNyandaMSkarbinskiJ. Performance of two malaria rapid diagnostic tests in febrile adult patients with and without human immunodeficiency virus-1 infection in Blantyre, Malawi. Am J Trop Med Hyg2012; 86: 199–202.
35.
ParkKSBaekKAKimDU. Evaluation of a new immunochromatographic assay kit for the rapid detection of norovirus in fecal specimens. Annals of laboratory medicine2012; 32: 79–81.
36.
BruinJPDiederenBM. Evaluation of the SD Bioline test, a new assay for detecting Legionella pneumophila serogroup 1 antigen in urine. The Journal of Infection2012; 64: 113–114.
37.
PrestonTJRatliffTMGomezD. Modified surface coatings and their effect on drug adsorption within the extracorporeal life support circuit. J Extra Corpor Technol2010; 42: 199–202.
38.
LamarcheYChowBBedardA. Thromboembolic events in patients on extracorporeal membrane oxygenation without anticoagulation. Innovations2010; 5: 424–429.
39.
ThiaraASAndersenVYVidemV. Comparable biocompatibility of Phisio- and Bioline-coated cardiopulmonary bypass circuits indicated by the inflammatory response. Perfusion2010; 25: 9–16.
40.
SohnNMarcouxJMycykT. The impact of different biocompatible coated cardiopulmonary bypass circuits on inflammatory response and oxidative stress. Perfusion2009; 24: 231–237.
41.
PappalardoFMajGScandroglioA. Bioline heparin-coated ECMO with bivalirudin anticoagulation in a patient with acute heparin-induced thrombocytopenia: the immune reaction appeared to continue unabated. Perfusion2009; 24: 135–137.
42.
ZimmermannAKWeberNAebertH. Effect of biopassive and bioactive surface-coatings on the hemocompatibility of membrane oxygenators. J Biomed Mater Res B Appl Biomater2007; 80: 433–439.
43.
PalatianosGMForoulisCNVassiliMI. A prospective, double-blind study on the efficacy of the bioline surface-heparinized extracorporeal perfusion circuit. Ann Thorac Surg2003; 76: 129–135.
44.
HarigFHohensteinBvon der EmdeJ. Modulating IL-6 and IL-10 levels by pharmacologic strategies and the impact of different extracorporeal circulation parameters during cardiac surgery. Shock2001; 16(Suppl 1): 33–38.
45.
MartensSMatheisGWimmer-GreineckerG. Heparin coating of the extracorporeal circuit combined with leukocyte filtration reduces coagulation activity, blood loss and blood product substitution. Int J Artif Organs2001; 24: 484–488.
46.
TayamaEHayashidaNAkasuK. Biocompatibility of heparin-coated extracorporeal bypass circuits: new heparin bonded bioline system. Artif Organs2000; 24: 618–623.
47.
BoltonFJFritzEPoyntonS. Rapid enzyme-linked immunoassay for detection of Salmonella in food and feed products: performance testing program. J AOAC Int2000; 83: 299–303.
48.
HarigFFeyrerRMahmoudFO. Reducing the post-pump syndrome by using heparin-coated circuits, steroids, or aprotinin. Thorac Cardiovasc Surg1999; 47: 111–118.
49.
van der KampKWMagielseCPElstrodtJM. Blood interaction with a Bioline heparin coated HIA-VAD: a study on calves. Int J Artif Organs1997; 20: 43–50.
50.
Teligui L, Dalmayrac E, Mabilleau G, et al. An ex vivo evaluation of blood coagulation and thromboresistance of two extracorporeal circuit coatings with reduced and full heparin dose. Interact Cardiovasc Thorac Surg 2014. DOI: 10.1093/icvts/ivu011.
51.
HussainiBETreanorPRHealeyNA. Evaluation of blood components exposed to coated arterial filters in extracorporeal circuits. Perfusion2009; 24: 317–323.
MehranRAymongEDAshbyDT. Safety of an aspirin-alone regimen after intracoronary stenting with a heparin-coated stent: final results of the HOPE (HEPACOAT and an Antithrombotic Regimen of Aspirin Alone) study. Circulation2003; 108: 1078–1083.
Flom-HalvorsenHIOvrumEBrosstadF. Effects of two differently heparin-coated extracorporeal circuits on markers for brain and myocardial dysfunction. Perfusion2002; 17: 339–345.
57.
SvenmarkerSHaggmarkSJanssonE. Use of heparin-bonded circuits in cardiopulmonary bypass improves clinical outcome. Scandinavian Cardiovascular Journal2002; 36: 241–246.
58.
WeberNWendelHPZiemerG. Hemocompatibility of heparin-coated surfaces and the role of selective plasma protein adsorption. Biomaterials2002; 23: 429–439.
59.
PalanzoDAZarroDLManleyNJ. Effect of Carmeda BioActive Surface coating versus Trillium Biopassive Surface coating of the oxygenator on circulating platelet count drop during cardiopulmonary bypass. Perfusion2001; 16: 279–283.
60.
OvrumETangenGOysteseR. Comparison of two heparin-coated extracorporeal circuits with reduced systemic anticoagulation in routine coronary artery bypass operations. J Thorac Cardiovasc Surg2001; 121: 324–330.
61.
SvenmarkerSSandstromEKarlssonT. Neurological and general outcome in low-risk coronary artery bypass patients using heparin coated circuits. Eur J Cardiothorac Surg2001; 19: 47–53.
62.
MunchKWolfMFGruffazP. Use of simple and complex in vitro models for multiparameter characterization of human blood-material/device interactions. J Biomater Sci Polym Ed2000; 11: 1147–1163.
63.
MesanaTCollartFCausT. Centrifugal pumps and heparin-coated circuits in surgical treatment of giant cerebral aneurysms. Artif Organs2000; 24: 431–436.
64.
KosterASangerSHansenR. Prevalence and persistence of heparin/platelet factor 4 antibodies in patients with heparin coated and noncoated ventricular assist devices. ASAIO J2000; 46: 319–322.
65.
StammersAHChristensenKALynchJ. Quantitative evaluation of heparin-coated versus non-heparin-coated bypass circuits during cardiopulmonary bypass. J Extra Corpor Technol1999; 31: 135–141.
66.
PalanzoDAZarroDLManleyNJ. Effect of surface coating on platelet count drop during cardiopulmonary bypass. Perfusion1999; 14: 195–200.
67.
WendelHPScheuleAMEcksteinFS. Haemocompatibility of paediatric membrane oxygenators with heparin-coated surfaces. Perfusion1999; 14: 21–28.
68.
BarstadRMHamersMJMollerAS. Monocyte procoagulant activity induced by adherence to an artificial surface is reduced by end-point immobilized heparin-coating of the surface. Thromb Haemost1998; 79: 302–305.
69.
BhujleRLiJShastriP. Influence of cardiopulmonary bypass on platelet and neutrophil accumulations in internal organs. ASAIO J1997; 43: M739–M744.
70.
HogevoldHEMoenOFosseE. Effects of heparin coating on the expression of CD11b, CD11c and CD62L by leucocytes in extracorporeal circulation in vitro. Perfusion1997; 12: 9–20.
71.
MoenOFosseEDregelidE. Centrifugal pump and heparin coating improves cardiopulmonary bypass biocompatibility. Ann Thorac Surg1996; 62: 1134–1140.
72.
FukutomiMKobayashiSNiwayaK. Changes in platelet, granulocyte, and complement activation during cardiopulmonary bypass using heparin-coated equipment. Artif Organs1996; 20: 767–776.
73.
TodaRSaigenjiHNishidaT. A case of ASD with SLE treated with Carmeda BioActive surface circuit in cardiopulmonary bypass system. Kyobu Geka1996; 49: 389–391.
74.
MoenOFosseEBratenJ. Differences in blood activation related to roller/centrifugal pumps and heparin-coated/uncoated surfaces in a cardiopulmonary bypass model circuit. Perfusion1996; 11: 113–123.
75.
SaenzALarranagaGAlvarezL. Heparin-coated circuit in coronary surgery. A clinical study. Eur J Cardiothorac Surg1996; 10: 48–53.
76.
MoenOFosseEBrockmeierV. Disparity in blood activation by two different heparin-coated cardiopulmonary bypass systems. Ann Thorac Surg1995; 60: 1317–1323.
77.
PalmerKEhrenHBenzR. Carmeda surface heparinization in neonatal ECMO systems: long-term experiments in a sheep model. Perfusion1995; 10: 307–313.
78.
RiesenfeldJOlssonPSanchezJ. Surface modification with functionally active heparin. Medical Device Technology1995; 6: 24–31.
79.
FosseEMoenOJohnsonE. Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass. Ann Thorac Surg1994; 58: 472–477.
80.
SellevoldOFBergTMReinKA. Heparin-coated circuit during cardiopulmonary bypass. A clinical study using closed circuit, centrifugal pump and reduced heparinization. Acta anaesthesiologica Scandinavica1994; 38: 372–379.
Vanden EyndenFCarrierMOuelletS. Avecor Trillium oxygenator versus noncoated Monolyth oxygenator: a prospective randomized controlled study. Journal of Cardiac Surgery2008; 23: 288–293.
83.
ErethMHNuttallGAClarkeSH. Biocompatibility of Trillium Biopassive Surface-coated oxygenator versus uncoated oxygenator during cardiopulmonary bypass. Journal of Cardiothoracic and Vascular Anesthesia2001; 15: 545–550. discussion 539–541.
84.
TevaearaiHTMuellerXMSeigneulI. Trillium coating of cardiopulmonary bypass circuits improves biocompatibility. Int J Artif Organs1999; 22: 629–634.
85.
WuBGerlitzBGrinnellBW. Polymeric coatings that mimic the endothelium: combining nitric oxide release with surface-bound active thrombomodulin and heparin. Biomaterials2007; 28: 4047–4055.
86.
HuangXJGuduruDXuZK. Blood compatibility and permeability of heparin-modified polysulfone as potential membrane for simultaneous hemodialysis and LDL removal. Macromol Biosci2011; 11: 131–140.
87.
ByunYJacobsHAKimSW. Binding kinetics of thrombin and antithrombin III with immobilized heparin using a spacer. ASAIO J1992; 38: M649–M653.
88.
ZhouZMeyerhoffME. Preparation and characterization of polymeric coatings with combined nitric oxide release and immobilized active heparin. Biomaterials2005; 26: 6506–6517.
89.
MajorTCBrantDOReynoldsMM. The attenuation of platelet and monocyte activation in a rabbit model of extracorporeal circulation by a nitric oxide releasing polymer. Biomaterials2010; 31: 2736–2745.
90.
AskewSCButlerARFlitneyFW. Chemical mechanisms underlying the vasodilator and platelet anti-aggregating properties of S-nitroso-N-acetyl-DL-penicillamine and S-nitrosoglutathione. Bioorg Med Chem1995; 3: 1–9.
DurandPYLanGBMarchalL. Evaluation of low-pressure arterial and venous clamps: electron microscopic study and possible clinical applications. J Reconstr Microsurg2000; 16: 465–471.
93.
SeftonMVSawyerAGorbetM. Does surface chemistry affect thrombogenicity of surface modified polymers?J Biomed Mater Res2001; 55: 447–459.
94.
SeyfertUTBiehlVSchenkJ. In vitro hemocompatibility testing of biomaterials according to the ISO 10993-4. Biomol Eng2002; 19: 91–96.
95.
VienkenJ. Testing biomaterials for application in artificial organs: impact of procedures, donor and patient properties. Prilozi/ Macedonian Academy of Sciences and Arts, Section of Biological and Medical Sciences2008; 29: 25–37.
96.
Cerda-CristernaBIFloresHPozos-GuillenA. Hemocompatibility assessment of poly(2-dimethylamino ethylmethacrylate) (PDMAEMA)-based polymers. Journal of Controlled Release2011; 153: 269–277.
97.
SinnSScheuermannTDeichelbohrerS. A novel in vitro model for preclinical testing of the hemocompatibility of intravascular stents according to ISO 10993-4. J Mater Sci Mater Med2011; 22: 1521–1528.
98.
TzonevaRHeuchelMGrothT. Fibrinogen adsorption and platelet interactions on polymer membranes. J Biomater Sci Polym Ed2002; 13: 1033–1050.
99.
HaycoxCLRatnerBD. In vitro platelet interactions in whole human blood exposed to biomaterial surfaces: insights on blood compatibility. J Biomed Mater Res1993; 27: 1181–1193.
100.
McClungWGBabcockDEBrashJL. Fibrinolytic properties of lysine-derivatized polyethylene in contact with flowing whole blood (Chandler loop model). J Biomed Mater Res A2007; 81: 644–651.
101.
TepeGSchmehlJWendelHP. Reduced thrombogenicity of nitinol stents – in vitro evaluation of different surface modifications and coatings. Biomaterials2006; 27: 643–650.
102.
van OeverenWTielliuIFde HartJ. Comparison of modified chandler, roller pump, and ball valve circulation models for in vitro testing in high blood flow conditions: application in thrombogenicity testing of different materials for vascular applications. Int J Biomater2012; 2012: 673163–673163. , 7 pp. DOI: 10.1155/2012/673163.
103.
MassaguerAEngelPPerez-del-PulgarS. Production and characterization of monoclonal antibodies against conserved epitopes of P-selectin (CD62P). Tissue Antigens2000; 56: 117–128.
104.
ColmanRW. Are hemostasis and thrombosis two sides of the same coin?J Exp Med2006; 203: 493–495.
105.
VersteegHHHeemskerkJWLeviM. New fundamentals in hemostasis. Physiol Rev2013; 93: 327–358.
106.
HamadOABackJNilssonPH. Platelets, complement, and contact activation: partners in inflammation and thrombosis. Adv Exp Med Biol2012; 946: 185–205.
107.
CardinalKOBonnemaGTHoferH. Tissue-engineered vascular grafts as in vitro blood vessel mimics for the evaluation of endothelialization of intravascular devices. Tissue Engineering2006; 12: 3431–3438.
108.
KellyBSHeffelfingerSCWhitingJF. Aggressive venous neointimal hyperplasia in a pig model of arteriovenous graft stenosis. Kidney Int2002; 62: 2272–2280.
109.
ShimizuKSugiyamaSAikawaM. Host bone-marrow cells are a source of donor intimal smooth- muscle-like cells in murine aortic transplant arteriopathy. Nat Med2001; 7: 738–741.
110.
FalkJTownsendLEVogelLM. Improved adherence of genetically modified endothelial cells to small-diameter expanded polytetrafluoroethylene grafts in a canine model. Journal of Vascular Surgery1998; 27: 902–908. discussion 908-909.
111.
HandaHBrisboisEJMajorTC. In vitro and in vivo study of sustained nitric oxide release coating using diazeniumdiolate-oped poly(vinyl chloride) matrix with poly(lactide–glycolide) additive. J Mater Chem B Mater Biol Med2013; 1: 3578–3587.
112.
SkrzypchakAMLafayetteNGBartlettRH. Effect of varying nitric oxide release to prevent platelet consumption and preserve platelet function in an in vivo model of extracorporeal circulation. Perfusion2007; 22: 193–200.
113.
MajorTCBrantDOBurneyCP. The hemocompatibility of a nitric oxide generating polymer that catalyzes S-nitrosothiol decomposition in an extracorporeal circulation model. Biomaterials2011; 32: 5957–5969.
114.
BrisboisEJHandaHMajorTC. Long-term nitric oxide release and elevated temperature stability with S-nitroso-N-acetylpenicillamine (SNAP)-doped Elast-eon E2As polymer. Biomaterials2013; 34: 6957–6966.
115.
MajorTCHandaHBrisboisEJ. The mediation of platelet quiescence by NO-releasing polymers via cGMP-induced serine 239 phosphorylation of vasodilator-stimulated phosphoprotein. Biomaterials2013; 34: 8086–8096.
116.
ZhangHAnnichGMMiskulinJ. Nitric oxide releasing silicone rubbers with improved blood compatibility: preparation, characterization, and in vivo evaluation. Biomaterials2002; 23: 1485–1494.
FrostMCReynoldsMMMeyerhoffME. Polymers incorporating nitric oxide releasing/generating substances for improved biocompatibility of blood-contacting medical devices. Biomaterials2005; 26: 1685–1693.
119.
AnnichGMMeinhardtJPMoweryKA. Reduced platelet activation and thrombosis in extracorporeal circuits coated with nitric oxide release polymers. Crit Care Med2000; 28: 915–920.
120.
VaughnMWKuoLLiaoJC. Estimation of nitric oxide production and reaction rates in tissue by use of a mathematical model. Am J Physiol1998; 274: H2163–H2176.
121.
RadomskiMWMoncadaS. The biological and pharmacological role of nitric oxide in platelet function. Ad Exp Med Biol1993; 344: 251–264.
122.
EigenthalerMUllrichHGeigerJ. Defective nitrovasodilator-stimulated protein phosphorylation and calcium regulation in cGMP-dependent protein kinase-deficient human platelets of chronic myelocytic leukemia. J Biol Chem1993; 268: 13526–13531.
123.
BusseRFlemingI. Regulation and functional consequences of endothelial nitric oxide formation. Ann Med1995; 27: 331–340.
124.
OelzeMMollnauHHoffmannN. Vasodilator-stimulated phosphoprotein serine 239 phosphorylation as a sensitive monitor of defective nitric oxide/cGMP signaling and endothelial dysfunction. Circ Res2000; 87: 999–1005.
125.
RatnerBDHorbettTAChapter II.3.5 – Evaluation of blood–materials interactions. In: BuddyDRAllanSHFrederickJS (eds). Biomaterials Science (Third Edition)., Waltham, MA: Academic Press2013, pp. 617–634.
126.
KawaiTAnnichGMMeinhardtJP. Effect of blood flow rate on thrombogenesis in a rabbit extracorporeal circulation model. ASAIO J1999; 45: 478–481.
127.
ZhangHAnnichGMMiskulinJ. Nitric oxide-releasing fumed silica particles: synthesis, characterization, and biomedical application. J Am Chem Soc2003; 125: 5015–5024.
128.
MeinhardtJPAnnichGMMiskulinJ. Thrombogenicity is not reduced when heparin and phospholipid bonded circuits are used in a rabbit model of extracorporeal circulation. ASAIO J2003; 49: 395–400.
GrabowskiEFDidisheimPLewisJC. Platelet adhesion to foreign surfaces under controlled conditions of whole blood flow: human vs rabbit, dog, calf, sheep, pig, macaque, and baboon. Trans Am Soc Artif Intern Organs1977; 23: 141–151.
131.
Ibarra-AlvaradoCGalleJMelicharVO. Phosphorylation of blood vessel vasodilator-stimulated phosphoprotein at serine 239 as a functional biochemical marker of endothelial nitric oxide/cyclic GMP signaling. Molecular Pharmacology2002; 61: 312–319.
132.
HandaHBElizabethJMajorTerryCAnnichGailMMeyerhoffMarkEBartlettRobertH. Prevention of thrombosis and infection using diazeniumdiolate-based nitric oxide releasing coatings in short-term and long-term animal models. J Am Chem Soc2013; 65: PMSE-181–PMSE-181.
133.
HandaHBrisboisEJMajorTC. and study of sustained nitric oxide release coating using diazeniumdiolate-doped poly(vinyl chloride) matrix with poly(lactide-co-glycolide) additive. J Mater Chem B Mater Biol Med2013; 1: 3578–3587.
134.
BatchelorMMReomaSLFleserPS. More lipophilic dialkyldiamine-based diazeniumdiolates: synthesis, characterization, and application in preparing thromboresistant nitric oxide release polymeric coatings. J Med Chem2003; 46: 5153–5161.
135.
Amoako KA, Montoya PJ, Major TC, et al. Fabrication and in vivo thrombogenicity testing of nitric oxide generating artificial lungs. J Biomed Mater Res A 2013.
136.
LaneDABowrySK. The scientific basis for selection of measures of thrombogenicity. Nephrol Dial Transplant1994; 9(Suppl 2): 18–28.
137.
RanucciMPazzagliaAIsgroG. Closed, phosphorylcholine-coated circuit and reduction of systemic heparinization for cardiopulmonary bypass: the intraoperative ECMO concept. Int J Artif Organs2002; 25: 875–881.
138.
ChatterjeeKGuoZVoglerEA. Contributions of contact activation pathways of coagulation factor XII in plasma. Journal of Biomedical Materials Research Part A2009; 90A: 27–34.
139.
AnnichGWhiteTDammD. Recombinant Kunitz protease inhibitory domain of the amyloid beta-protein precursor as an anticoagulant in venovenous extracorporeal circulation in rabbits. Thromb Haemost1999; 82: 1474–1481.
EbertRF. Index of variant human fibrinogens, Boca Raton, Fla.: CRC Press, 1991.434.
142.
ConnGKidaneAGPunshonG. Is there an alternative to systemic anticoagulation, as related to interventional biomedical devices?Expert Rev Med Devices2006; 3: 245–261.
143.
LauCLPostherKEStephensonGR. Mini-circuit cardiopulmonary bypass with vacuum assisted venous drainage: feasibility of an asanguineous prime in the neonate. Perfusion1999; 14: 389–396.
144.
LindhoutT. Biocompatibility of extracorporeal blood treatment. Selection of haemostatic parameters. Nephrol Dial Transplant1994; 9(Suppl 2): 83–89.
145.
WendelHPZiemerG. Coating-techniques to improve the hemocompatibility of artificial devices used for extracorporeal circulation. Eur J Cardiothorac Surg1999; 16: 342–350.
146.
MaruyamaI. Biology of endothelium. Lupus1998; 7(Suppl 2): S41–S43.
147.
BossavyJPCadroyYSakariassenK. Nonfractionated heparin fails to inhibit arterial thrombosis in a human ex vivo thrombosis model. Ann Vasc Surg1999; 13: 393–401.
148.
BossavyJPSakariassenKSRubsamenK. Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of arterial thrombosis. Arterioscler Thromb Vasc Biol1999; 19: 1348–1353.
149.
AddonizioVPColmanRW. Platelets and extracorporeal circulation. Biomaterials1982; 3: 9–15.
150.
GorogDAFusterV. Platelet function tests in clinical cardiology: unfulfilled expectations. Journal of the American College of Cardiology2013; 61: 2115–2129.
151.
HeemskerkJWMattheijNJCosemansJM. Platelet-based coagulation: different populations, different functions. Journal of Thrombosis and Haemostasis2013; 11: 2–16.
152.
ColmanRW. Platelet and neutrophil activation in cardiopulmonary bypass. The Annals of Thoracic Surgery1990; 49: 32–34.
153.
AdrianKSkogbyMFribergLG. The effect of s-nitroso-glutathione on platelet and leukocyte function during experimental extracorporeal circulation. Artif Organs2003; 27: 570–575.
154.
HongJLarssonAEkdahlKN. Contact between a polymer and whole blood: sequence of events leading to thrombin generation. J Lab Clin Med2001; 138: 139–145.
155.
SatoYHiramatsuYHommaS. Phosphodiesterase type 4 inhibitor rolipram inhibits activation of monocytes during extracorporeal circulation. J Thorac Cardiovasc Surg2005; 130: 346–350.
156.
SeeburgerJHoffmannJWendelHP. Gene expression changes in leukocytes during cardiopulmonary bypass are dependent on circuit coating. Circulation2005; 112: I224–I228.
157.
TreacherDFSabbatoMBrownKA. The effects of leucodepletion in patients who develop the systemic inflammatory response syndrome following cardiopulmonary bypass. Perfusion2001; 16(Suppl): 67–73.
158.
YoshizakiTTabuchiNvan OeverenW. PMEA polymer-coated PVC tubing maintains anti-thrombogenic properties during in vitro whole blood circulation. Int J Artif Organs2005; 28: 834–840.
159.
HernandezMRAlvarez-GuerraMEscolarG. The hemostatic agent ethamsylate promotes platelet/leukocyte aggregate formation in a model of vascular injury. Fundam Clin Pharmacol2004; 18: 423–430.
160.
KlinkhardtUBauersachsRAdamsJ. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin Pharmacol Ther2003; 73: 232–241.
161.
NomuraSTandonNNNakamuraT. High-shear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. Atherosclerosis2001; 158: 277–287.
162.
HuangSMulvihillERFarrellDH. Biosynthesis of human fibrinogen. Subunit interactions and potential intermediates in the assembly. Journal of Biological Chemistry1993; 268: 8919–8926.
163.
GeerCBStaskoNARusIA. Influence of glutathione and its derivatives on fibrin polymerization. Biomacromolecules2008; 9: 1876–1882.
164.
GoudCDiPieroALocketteWE. Cyclic GMP-independent mechanisms of nitric oxide-induced vasodilation. Gen Pharmacol1999; 32: 51–55.
165.
BegonjaAJTeichmannLGeigerJ. Platelet regulation by NO/cGMP signaling and NAD(P)H oxidase-generated ROS. Blood Cells Mol Dis2006; 36: 166–170.
166.
LeonciniGBruzzeseDSignorelloMG. The L-arginine/NO pathway in the early phases of platelet stimulation by collagen. Biochem Pharmacol2005; 69: 289–296.
167.
RadomskiMWVallancePWhitleyG. Platelet adhesion to human vascular endothelium is modulated by constitutive and cytokine induced nitric oxide. Cardiovasc Res1993; 27: 1380–1382.
168.
RadomskiMWPalmerRMMoncadaS. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun1987; 148: 1482–1489.
169.
AktasBUtzAHoenig-LiedlP. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo/ex vivo studies. Stroke2003; 34: 764–769.
170.
ButtEAbelKKriegerM. cAMP- and cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein (VASP) in vitro and in intact human platelets. J Biol Chem1994; 269: 14509–14517.
171.
SmolenskiABachmannCReinhardK. Analysis and regulation of vasodilator-stimulated phosphoprotein serine 239 phosphorylation in vitro and in intact cells using a phosphospecific monoclonal antibody. J Biol Chem1998; 273: 20029–20035.
172.
SmolenskiABurkhardtAMEigenthalerM. Functional analysis of cGMP-dependent protein kinases I and II as mediators of NO/cGMP effects. Naunyn Schmiedebergs Arch Pharmacol1998; 358: 134–139.
173.
AszodiAPfeiferAAhmadM. The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. EMBO J1999; 18: 37–48.
174.
HauserWKnobelochKPEigenthalerM. Megakaryocyte hyperplasia and enhanced agonist-induced platelet activation in vasodilator-stimulated phosphoprotein knockout mice. Proc Natl Acad Sci USA1999; 96: 8120–8125.
